Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm

Table 6 Comparison of contrast-enhanced ultrasound characteristics between hepatic neuroendocrine tumor and hepatic neuroendocrine carcinoma groups, n (%)

Contrast-enhanced Ultrasound characteristics		hNET group, n = 35	hNEC group, n = 20	t/χ2	P value
Initial enhancement time in s		16.83 ± 5.08	16.28 ± 4.93	0.834	0.854
Washout to iso-enhancement time in s		30.84 ± 10.38	27.68 ± 9.74	1.856	0.804
Washout to hypo-enhancement time in s		65.28 ± 37.84	51.72 ± 31.85	1.152	0.833
Enhancement level at arterial phase	High	33 (94.3)	20 (100.0)	1.186	0.276
	Equal	2 (5.7)	0 (0)
	Low	0 (0)	0 (0)
Enhancement level at portal venous phase	Equal	7 (20.0)	0 (0)	4.583	0.032
	Low	28 (80.0)	20 (100.0)
Enhancement level at late phase	Equal	1 (2.9)	1 (5.0)	-	1.0001
	Low	34 (97.1)	19 (95.0)
Enhancement forms	Fast forward and fast out	34 (97.1)	19 (95.0)	-	1.0001
	Equal/slow forward and fast out	1 (2.9)	1 (5.0)
Enhancement forms	Uniform	28 (80.0)	5 (25.0)	16.042	0.000
	Non-uniform	7 (20.0)	15 (75.0)
Tumor vasculature	Yes	15 (42.9)	19 (95.0)	14.661	0.000
	No	20 (57.1)	1 (5.0)
Tumor necrosis	Yes	10 (28.6)	6 (30.0)	0.013	0.911
	No	25 (71.4)	14 (70.0)
Capsule enhancement	Yes	6 (17.1)	1 (5.0)	-	0.4021
	No	29 (82.9)	19 (95.0)

¹Represent Fisher’s exact test. hNET: Hepatic neuroendocrine tumor; hNEC: Hepatic neuroendocrine carcinoma.